BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38171332)

  • 21. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
    Gargett T; Truong N; Ebert LM; Yu W; Brown MP
    Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The roles of NADPH and isocitrate dehydrogenase in cochlear mitochondrial antioxidant defense and aging.
    White K; Someya S
    Hear Res; 2023 Jan; 427():108659. PubMed ID: 36493529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells.
    Huang Y; Si X; Shao M; Teng X; Xiao G; Huang H
    J Hematol Oncol; 2022 Mar; 15(1):38. PubMed ID: 35346311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
    Gumber D; Wang LD
    EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exhaustion of CAR T cells: potential causes and solutions.
    Kouro T; Himuro H; Sasada T
    J Transl Med; 2022 May; 20(1):239. PubMed ID: 35606821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
    Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
    Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor.
    Zhao J; Dong J; Deng C; Zhang Q; Sun S; Li H; Bai Y; Deng H
    Oncoimmunology; 2023; 12(1):2265703. PubMed ID: 37808405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies.
    Greco B; Malacarne V; De Girardi F; Scotti GM; Manfredi F; Angelino E; Sirini C; Camisa B; Falcone L; Moresco MA; Paolella K; Di Bono M; Norata R; Sanvito F; Arcangeli S; Doglioni C; Ciceri F; Bonini C; Graziani A; Bondanza A; Casucci M
    Sci Transl Med; 2022 Jan; 14(628):eabg3072. PubMed ID: 35044789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enasidenib in mutant
    Stein EM; DiNardo CD; Pollyea DA; Fathi AT; Roboz GJ; Altman JK; Stone RM; DeAngelo DJ; Levine RL; Flinn IW; Kantarjian HM; Collins R; Patel MR; Frankel AE; Stein A; Sekeres MA; Swords RT; Medeiros BC; Willekens C; Vyas P; Tosolini A; Xu Q; Knight RD; Yen KE; Agresta S; de Botton S; Tallman MS
    Blood; 2017 Aug; 130(6):722-731. PubMed ID: 28588020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isocitrate dehydrogenase 2 contributes to radiation resistance of oesophageal squamous cell carcinoma via regulating mitochondrial function and ROS/pAKT signalling.
    Chen X; Zhuo S; Xu W; Chen X; Huang D; Sun X; Cheng Y
    Br J Cancer; 2020 Jul; 123(1):126-136. PubMed ID: 32367071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
    Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
    Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
    Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells.
    Zhang X; Zhang C; Qiao M; Cheng C; Tang N; Lu S; Sun W; Xu B; Cao Y; Wei X; Wang Y; Han W; Wang H
    Cancer Cell; 2022 Nov; 40(11):1407-1422.e7. PubMed ID: 36240777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function.
    Wenes M; Jaccard A; Wyss T; Maldonado-Pérez N; Teoh ST; Lepez A; Renaud F; Franco F; Waridel P; Yacoub Maroun C; Tschumi B; Dumauthioz N; Zhang L; Donda A; Martín F; Migliorini D; Lunt SY; Ho PC; Romero P
    Cell Metab; 2022 May; 34(5):731-746.e9. PubMed ID: 35452600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 36. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies.
    Zhang ZZ; Wang T; Wang XF; Zhang YQ; Song SX; Ma CQ
    Pharmacol Res; 2022 Jan; 175():106036. PubMed ID: 34920118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular remission and response patterns in patients with mutant-
    Stein EM; DiNardo CD; Fathi AT; Pollyea DA; Stone RM; Altman JK; Roboz GJ; Patel MR; Collins R; Flinn IW; Sekeres MA; Stein AS; Kantarjian HM; Levine RL; Vyas P; MacBeth KJ; Tosolini A; VanOostendorp J; Xu Q; Gupta I; Lila T; Risueno A; Yen KE; Wu B; Attar EC; Tallman MS; de Botton S
    Blood; 2019 Feb; 133(7):676-687. PubMed ID: 30510081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions.
    Nguyen DT; Liu R; Ogando-Rivas E; Pepe A; Pedro D; Qdaisat S; Nguyen NTY; Lavrador JM; Golde GR; Smolchek RA; Ligon J; Jin L; Tao H; Webber A; Phillpot S; Mitchell DA; Sayour EJ; Huang J; Castillo P; Gregory Sawyer W
    Acta Biomater; 2023 Dec; 172():466-479. PubMed ID: 37788737
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
    Bergaggio E; Riganti C; Garaffo G; Vitale N; Mereu E; Bandini C; Pellegrino E; Pullano V; Omedè P; Todoerti K; Cascione L; Audrito V; Riccio A; Rossi A; Bertoni F; Deaglio S; Neri A; Palumbo A; Piva R
    Blood; 2019 Jan; 133(2):156-167. PubMed ID: 30455381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.